Paramount Skydance Corporation has extended the expiration dates for its cash tender and exchange offers on various notes issued by Warner Bros. Discovery entities to October 6, 2026. This extension aligns the settlement dates with the anticipated closing of Paramount's proposed acquisition of Warner Bros. Discovery. Approximately 67% to 75% of the notes have been tendered so far, but the company expects further participation as the offers remain open. The company also updated terms of new notes to match upcoming senior secured second lien notes, reflecting ongoing financial structuring ahead of the acquisition.
Paramount Skydance Corporation's announcement on extending expiration dates for tender and exchange offers is presented here with Pluang's Media-sector market data as of Sep 28, 2026 18:51 WIB. Of 45 priced Media-sector US stocks tradable on Pluang, 17 rose and 23 fell today. Notable prices include FOX at USD 56.01 with a 1-day change of -0.94%, DJT at USD 9.06 down 0.88%, and GOOGL at USD 341.25 down 0.78%.
Between Sept. 21 and Sept. 27, Strategy acquired 1,665 Bitcoin at an average price of $85,681 each, increasing its total holdings to 847,666 BTC valued at approximately $63.95 billion. The company financed this purchase partly by selling $246.2 milli...
Paramount Skydance Corporation announced plans to offer $44.4 billion in senior secured notes to qualified institutional buyers to help finance its acquisition of Warner Bros. Discovery and repay existing debt. The offering includes U.S. dollar- and ...
The Federal Reserve has increased its benchmark interest rate to a range of 3.75% to 4.00%, the first hike since 2023, with another possible before year-end. This move makes high-yield savings accounts more attractive, as they offer significantly hig...
Cellebrite DI Ltd. is under investigation by Kaplan Fox & Kilsheimer LLP for potential securities violations after the company missed its second-quarter revenue targets and cut its full-year guidance. The company reported $507.8 million in annual rec...
TransCode Therapeutics announced updated Phase 1a trial results for TTX-MC138, an RNA-based cancer therapy targeting advanced solid tumors. Among 14 evaluable patients, 71.4% achieved stable disease, with over half maintaining control through three m...
